{"id":"NCT01237327","sponsor":"Pfizer","briefTitle":"Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer","officialTitle":"Follow-up of the Study 971-ONC-0028-080: Exemestane Versus Megestrol Acetate In Postmenopausal Patients With Metastatic Breast Cancer, Failing Anti-Estrogens: An Open-Label, Randomized, Parallel-Group, Phase III Comparative Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2001-11","primaryCompletion":"2007-12","completion":"2009-12","firstPosted":"2010-11-09","resultsPosted":"2011-03-14","lastUpdate":"2011-05-06"},"enrollment":84,"design":{"allocation":null,"model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Metastatic Breast Cancer"],"interventions":[{"type":"DRUG","name":"Megestrol acetate","otherNames":["Megace"]},{"type":"DRUG","name":"exemestane (Aromasin)","otherNames":["Aromasin"]}],"arms":[{"label":"1","type":"ACTIVE_COMPARATOR"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"Long term efficacy of exemestane as compared to megestrol acetate in the treatment of women with natural or induced postmenopausal status with advanced breast cancer whose disease has progressed following anti-estrogens or anti-estrogens plus chemotherapy and who had participated on an original study of exemestane vs megestrol : study 971-ONC-0028-080.","primaryOutcome":{"measure":"Overall Survival","timeFrame":"Every 12 weeks up to 6 years","effectByArm":[{"arm":"Exemestane","deltaMin":29.2,"sd":null},{"arm":"Megestrol Acetate","deltaMin":16.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.3348"}]},"eligibility":{"minAge":null,"sex":"FEMALE","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":7,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=971-ONC-0028-094&StudyName=Open%20Label%20Randomized%20Controlled%20Multicenter%20Follow%20Up%20Study%20Of%20Subjects%20Who%20Participated%20In%20An%20Original%20Protocol%20Of%20Exemestane%20Vs"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":41},"commonTop":["Cough","Sweating increased","Nausea","Weight increased","Fatigue"]}}